Abstract-Hypertension is associated with an increased risk of thrombosis that appears to involve an interaction between the renin-angiotensin system and hemostasis. In this study we determined whether angiotensin II-mediated thrombosis occurs in arterioles and/or venules and assessed the involvement of type 1 (AT 1 ), type 2 (AT 2 ), and type 4 (AT 4 ) angiotensin II receptors, as well as receptors for endothelin 1 and bradykinin 1 and 2 in angiotensin II-enhanced microvascular thrombosis. Thrombus development in mouse cremaster microvessels was quantified after light/dye injury using the time of onset of the thrombus and time to blood flow cessation. Wild-type and AT 1 receptor-deficient mice were implanted with an angiotensin II-loaded ALZET pump for 2 weeks. Angiotensin II administration in both wild-type and AT 1 receptor-deficient mice significantly accelerated thrombosis in arterioles. Genetic deficiency and pharmacological antagonism of AT 1 receptors did not alter the thrombosis response to angiotensin II. Isolated murine platelets aggregated in response to low (picomolar) but not high (nanomolar) concentrations of angiotensin II. The platelet aggregation response to angiotensin II depended on AT 1 receptors. Antagonism of AT 2 receptors in vivo significantly prolonged the onset of angiotensin II-enhanced thrombosis, whereas an AT 4 receptor antagonist prolonged the time to flow cessation. Selective antagonism of either endothelin 1 or bradykinin 1 receptors largely prevented both the onset and flow cessation responses to chronic angiotensin II infusion. Our findings indicate that angiotensin II induced hypertension is accompanied by enhanced thrombosis in arterioles, and this response is mediated by a mechanism that involves AT 2 , AT 4 , bradykinin 1, and endothelin 1 receptor-mediated signaling. 
T he risk factors for cardiovascular disease (CVD), including hypertension, are often accompanied by alterations in platelet function and coagulation, which translate clinically as an increased risk for thrombosis. 1 Although the higher incidence of thromboembolic events associated with CVD risk factors is more often manifested in large arteries, large vein involvement is also supported by epidemiological evidence. 2 Animal studies have also revealed that hypercholesterolemia enhances thrombus formation in arterioles but not in venules. 3 Enhanced thrombus formation in the microvasculature may contribute to the small vessel disease that can accompany chronic hypertension and other CVD risk factors, potentially leading to microinfarctions in the brain and heart. However, it remains unclear whether other cardiovascular risk factors, such as hypertension, also promote thrombosis in the microvasculature.
Abnormalities in platelet activation/reactivity, coagulation, and fibrinolysis are commonly associated with hypertension, which could explain the increased risk for thrombus formation in this patient population. 1 An activated renin-angiotensin system (RAS) and its key mediator, angiotensin II (Ang II), have been implicated in the prothrombotic state associated with hypertension. 1, 4 This contention is supported by clinical evidence that hypertensive patients treated with either an angiotensin-converting enzyme inhibitor or an Ang II receptor blocker exhibit a lower incidence of prothrombotic events. 5, 6 Furthermore, Ang II administration in experimental animals recapitulates many of the abnormalities in platelet function and the enhanced thrombosis in large arteries described in patients with hypertension. 7, 8 Whether Ang II and its receptors also promote thrombus formation in the microvasculature remains unclear.
The physiological and pathophysiological responses to Ang II involve the participation of a variety of mediators, cell surface receptors, and intracellular signaling pathways. Ang II can directly activate cells by engaging with Ang II type 1 (AT 1 ), AT 2 , and AT 4 receptors 9 or do so indirectly via the generation of endothelin 1 and/or bradykinin, 10, 11 which then interact with their own receptor to mediate cell activation. A role for bradykinin in arterial thrombogenesis is supported by reports describing delayed thrombosis in mice that are genetically deficient in kininogen (a precursor to bradykinin in the kallikrein-kinin system) 12 and by the ability of bradykinin to induce tissue factor expression and to enhance the procoagulant properties of endothelial cells. 13 Endothelin 1, which is linked to Ang II via the AT 1 receptor, 14 can also activate the coagulation cascade and induce microvascular thrombosis. 15, 16 The overall objectives of the present study were to determine whether Ang II hypertension alters thrombus formation in the microvasculature and to assess the involvement of receptors for Ang II (AT 1 r, AT 2 r, and AT 4 r), bradykinin (BK-1r and BK-2r), and endothelin 1 (ET-1r) in Ang II-mediated microvascular thrombogenesis. Our findings indicate that Ang II enhances thrombus formation in the microvasculature. Although AT 1 r on platelets was shown to mediate Ang II-induced platelet aggregation in vitro, this receptor population does not appear to contribute to microvascular thrombus formation. AT 2 r receptor activation appears to mediate the initiation (onset) of Ang II-enhanced microvascular thrombosis, whereas AT 4 r activation contributes to the stabilization phase (blood flow cessation) of the thrombosis response. Antagonism of either the BK-1r or ET-1r largely prevented the accelerated onset and blood flow cessation responses elicited in arterioles by Ang II.
Methods

Mice
Male C57BL/6 (wild-type [WT]) mice and Ang II receptor type 1a knockout (B6.129P2-Agtr1a tm1Unc /J) mice (AT 1 r Ϫ/Ϫ ) were obtained from Jackson Laboratories (Bar Harbor, ME) or bred in the Louisiana State University Health Sciences Center animal facility. The mice were housed under specific pathogen-free conditions and fed standard laboratory chow and water until the desired age (6 to 8 weeks). All of the experimental procedures involving the use of animals were reviewed and approved by the institutional animal care and use committee of Louisiana State University Health Sciences Center and performed according to the criteria outlined by the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Ang II Infusion
Saline or Ang II (1 g/kg per minute) was infused over 14 days using micro-osmotic pumps (ALZET), which were implanted subcutaneously in the intrascapular region of isofluorane anesthetized mice. A topical antibiotic (Neosporin) was applied to prevent postoperative infection at the site of implantation. Blood pressure was monitored with a computerized tail cuff system (Hatteras Instruments, Inc).
Induction of Microvascular Thrombosis in Cremaster Muscle
On day 15 after micro-osmotic pump implantation, the cremaster muscle prepared for intravital microscopic observation and microvascular thrombosis was induced by the light/dye method, as described previously. 17 Thrombus formation was quantified by determining the time of onset of platelet deposition/aggregation within the microvessel (onset time) and the time required for complete flow cessation for Ն30 seconds (cessation time) after light/dye injury. For a more detailed method, see the online Data Supplement (available at http://hyper.ahajournals.org).
In Vitro Platelet Aggregation
Platelet-rich plasma collected from mice was used to quantify Ang II-and thrombin-induced platelet aggregation using a low-angle light scattering technique, as described previously. 17 For a more detailed description of these procedures, see the online Data Supplement.
Murine Plasminogen Activator 1 Assay
Plasma plasminogen activator 1 (PAI-1) was measured in control mice and in mice with an Ang II pump using a murine PAI-1 total antigen ELISA kit (Innovative Research).
Experimental Design
Thrombus formation in cremaster microvessels after light/dye exposure was determined in the following experimental groups: (1) WT mice implanted with a saline-or Ang II-loaded pump (WT/Ang II); (2) WT/Ang II mice treated with either the AT 1 r antagonist losartan (25 mg/kg per day, Merck & Co, Inc) in drinking water for 7 days before the experiment, 18 the AT 2 antagonist PD123319 (30 mg/kg, IV, Sigma Chemicals) 19 
Statistical Analyses
All of the data are presented as meanϮSEM, with Ն5 mice per group. For comparisons between groups, a 1-way ANOVA was used followed by either a Newman-Keuls or Student t test.
Results
Ang II pump implantation yielded a significantly elevated blood pressure in WT mice (138.4Ϯ3.0 mm Hg) compared with WT mice with a saline-loaded pump (104.1Ϯ4.6 mm Hg) or WT mice not subjected to pump implantation (103Ϯ2.3 mm Hg). The values for shear rate in microvessels and arterial blood pressure in anesthetized mice at 10 minutes after fluorescein isothiocyanate-dextran administration are summarized in Table S1 (see the online Data Supplement at http://hyper.ahajournals.org). Shear rates did not differ significantly between the experimental groups for both arterioles and venules. Selective antagonism of AT 1 r or AT 2 r significantly blunted the Ang II-induced increase in blood pressure in WT mice. The Ang II-induced hypertension was not observed in AT 1 r Ϫ/Ϫ mice. Because WT mice without pump implantation and WT mice with saline pumps did not differ relative to the time required to elicit both the onset of thrombosis and complete flow cessation, the 2 groups were pooled and used as controls ( Figure 1SC and 1SD). As reported previously, both onset and flow cessation times in control mice were markedly longer in arterioles than in the paired venules. 21 In arterioles, Ang II infusion significantly accelerated both the onset (initiation) and cessation phases of light/dye-induced thrombus formation ( Figure 1SC ). Although a similar tendency was noted in venules, these changes did not reach statistical significance. Because thrombus formation in arterioles is far more responsive to Ang II infusion than in venules, all of the subsequent figures focus on the arteriolar responses. Figure 1A illustrates the effects of pharmacological antagonism (losartan) or genetic deletion of AT 1 r on thrombus formation in arterioles of mice with an Ang II pump. The data show that the time for initiation (onset) of thrombus formation in losartan-treated WT/Ang II mice is significantly reduced (accelerated initiation of thrombus formation) compared with untreated WT/Ang II mice, whereas the response to Ang II infusion was not altered in AT 1 r Ϫ/Ϫ mice. The time to flow cessation in mice with an Ang II pump was not affected in either AT 1 r Ϫ/Ϫ mice or in WT mice treated with losartan. A comparison of the thrombosis responses between arterioles of WT and AT 1 r Ϫ/Ϫ without pumps revealed an accelerated initiation (onset) of thrombosis with no difference in the time to flow cessation ( Figure 1B) . A similar enhancement of thrombosis (PϽ0.05) was noted in venules of AT 1 r Ϫ/Ϫ (onset: 0.43Ϯ0.084 minutes; cessation: 4.6Ϯ0.3 minutes; nϭ3) compared with WT (onset: 1.84Ϯ0.18 minutes; cessation: 9.36Ϯ1.24 minutes; nϭ4) mice. Figure 1C illustrates the effects of PD123319 on the Ang II-enhanced thrombosis response of arterioles to light/dye injury. AT 2 r blockade resulted in a significant recovery in the time to onset of thrombosis but did not alter the time to flow cessation. Figure 1D illustrates how treatment of AT 1 r Ϫ/Ϫ mice with PD123319 affected the Ang II-enhanced thrombosis responses. The combined effect of AT 1 r deficiency and AT 2 r blockade was similar to that noted with PD123319 treatment alone, that is, a significant prolongation of thrombus initiation without a change in the cessation phase. Figure 2 shows that treatment of WT mice with an AT 4 r antagonist (Divalinal) has no effect on Ang II-enhanced initiation of thrombosis (onset), but it significantly prolongs the time required for complete flow cessation. Figure 3 summarizes the actions of BK-1r and BK-2r antagonists ( Figure 3A) and an ET-1r antagonist ( Figure 3B ) on Ang II-enhanced arteriolar thrombosis. These experiments reveal that blocking either the BK-1r or ET-1Ar completely prevents both the accelerated onset and cessation of thrombosis normally associated with Ang II infusion.
The response of plasma PAI-1 to Ang II infusion is shown in Figure S2 . The data show that PAI-1 is significantly elevated in Ang II pump mice compared with control mice (1.84Ϯ0.2 versus 1.0Ϯ0.21 ng/mL).
In vitro studies were undertaken to determine whether exposure of murine platelets to Ang II elicits cell aggregation (Figure 4) . These experiments revealed that, whereas micromolar and nanomolar concentrations of Ang II do not induce platelet aggregation (Figure 4C the same Ang II concentration ( Figure 4C ). The half-maximum aggregation response to Ang II (EC 50 ) was found to be 10 pmol/L ( Figure 4A ), which yielded a normalized mean aggregation velocity of 21.3Ϯ3.1 relative units. As shown in Figure 3SA (see the online Data Supplement), thrombin elicits a dose-dependent aggregation response in murine platelets in the nanomolar range (or from 0.25 to 4.16 U/mL). The EC 50 for thrombin in WT platelets was 0.63U/mL (6.77 nmol/L). Exposure of platelets from AT 1 r Ϫ/Ϫ mice to the thrombin EC 50 concentration produced an aggregation response that was enhanced (PϽ0.05) by Ϸ35% (from 132.0Ϯ13.4 to 177.8Ϯ3.4 relative units).
In a separate group of platelet preparations ( Figure 3SB ), we determined whether platelet preparations that were not responsive to 1 nmol/L of Ang II were also nonresponsive to thrombin. These experiments revealed that previous exposure to 1 nmol/L of Ang II enhances, rather than blunts, the platelet aggregation response to thrombin. Ang II exposure (10 pM) did not exert this alteration in the aggregation response to thrombin.
Discussion
Hypertensive patients exhibit an increased risk for thrombosis, which links this CVD risk factor to diseases such as stroke and myocardial infarction. Although abnormalities in platelet function, coagulation/fibrinolysis, and vessel wall activation have been implicated in the prothrombotic phenotype associated with hypertension, 4,22 the mechanisms underlying this complication of hypertension remain poorly understood. The RAS has received considerable attention in this regard because drugs that target the RAS significantly reduce the incidence of thrombosis in hypertensive patients, animal studies have revealed a similar role for the RAS in the accelerated carotid artery thrombosis associated with renovascular hypertension, 1, 23 and a functional link between RAS activation and impaired fibrinolysis via PAI-1 has been demonstrated. 24, 25 The present study provides evidence that the prothrombogenic effects of Ang II are not limited to large arteries and extend to the microvasculature. The accelerated microvascular thrombosis associated with chronic Ang II infusion is most striking in arterioles, with a less reproducible response noted in venules. Ang II infusion was also associated with significantly elevated plasma PAI-1 levels. Although murine platelets were shown to respond to low picomolar levels of Ang II in an AT 1 r-dependent manner, the Ang II-enhanced arteriolar thrombosis appears to occur independently of AT 1 r activation. Instead, our findings im- plicate AT 2 r in the initiation (onset) and AT 4 r in the flow cessation phases of Ang II-mediated thrombosis. BK-1r and ET-1Ar (unlike AT 2 r and AT 4 r) appear to contribute to both the initiation and flow cessation phases of Ang II-enhanced thrombus formation.
Patients with hypertension exhibit evidence for platelet activation and increased aggregation, 5 responses that can be reproduced by infusion of Ang II in animals. 7 These observations are consistent with evidence that human platelets express a low density of high-affinity AT 1 receptors that bind to Ang II. 26, 27 Because the Ang II-mediated enhancement of light/dye-induced thrombosis may reflect a direct action of the peptide on platelets, we evaluated whether Ang II promotes the aggregation of murine platelets. We found that picomolar levels of Ang II elicit a brisk aggregation response of WT platelets, whereas nanomolar and higher concentrations have no effect. The observed insensitivity to higher concentrations of Ang II was not observed with thrombin and may reflect rapid desensitization of AT 1 receptors, 27 which could account for the previously reported absence of aggregation of rat platelets after exposure to 10 Ϫ7 M Ang II. 7 A role for receptor desensitization is supported by a report that used AT 1 a receptor-transfected CHO-K1 cells to demonstrate AT 1 r within 50 seconds after exposure to 10 Ϫ9 M Ang II. 27 Despite desensitization of AT 1 r after Ang II exposure, the platelets may remain responsive to other agonists like thrombin. We show in this study that previous exposure of murine platelets to 10 Ϫ9 M Ang II does not diminish the platelet aggregation response to thrombin; instead, it is enhanced, suggesting that the signaling mechanisms within platelets are not compromised by the high levels of Ang II. The enhanced sensitivity of Ang II-exposed platelets to thrombin is consistent with a previous report that describes an increased thrombin receptor expression in smooth muscle cells exposed to 10 Ϫ9 M Ang II for 2 hours. 28 In our model, the Ang II-mediated platelet aggregation appears to depend on AT 1 r inasmuch as platelets derived from AT 1 r Ϫ/Ϫ mice did not respond to picomolar levels of Ang II. A role for AT 2 r and AT 4 r in Ang II-mediated aggregation appears unlikely based on the complete absence of an aggregation response by AT 1 r-deficient platelets and based on studies of human platelets. 26 These findings, when considered with our in vivo data, suggest that Ang II-enhanced thrombus formation likely reflects an action of Ang II on the vessel wall rather than on platelets.
The absence of a role for AT 1 r in the enhanced arteriolar thrombus formation associated with chronic Ang II infusion contrasts with previous reports describing the effectiveness of AT 1 r antagonists in blunting the platelet-endothelial cell adhesion induced in venules by acute Ang II exposure 29 or by hypercholesterolemia. 18 Because bone marrow chimeras produced from AT 1 r Ϫ/Ϫ mice have revealed that the enhanced platelet adhesion response to hypercholesterolemia is mediated by vascular wall (not platelet) AT 1 r, it is possible that the discrepancy between the roles of AT 1 r in platelet adhesion versus thrombosis may relate to inherent differences between arterioles and venules. 30 Although the present study fails to implicate AT 1 r in the arteriolar thrombosis associated with chronically elevated Ang II, we do provide some evidence for a protective role of AT 1 r in the initiation of thrombosis in both arterioles and venules in the absence of exogenous Ang II. This observation is consistent with our in vitro aggregation results that show an exaggerated platelet aggregation response of AT 1 r Ϫ/Ϫ platelets to thrombin. Previous studies by others have demonstrated a link between Ang II and the kallikrein-kinin system in the modulation of coagulation, thrombus formation, 31 and fibrinolysis (impaired because of increased PAI-1 expression). 32 BK-1 receptors are induced after tissue injury, inflammation, and Ang II infusion. 11, 33 A prothrombotic role for bradykinin is supported by the prolonged time for carotid artery occlusion after thrombus induction in mice genetically deficient in kininogen, the substrate for kallikrein-mediated generation of bradykinin. 12 The BK-1r induction may occur as a result of sustained BK-2r activation and consequent desensitization. 33 The comparable effects of the AT 2 r and BK-1r antagonists in prolonging the initiation (onset) of thrombosis during chronic Ang II infusion are also consistent with an interaction between angiotensin and bradykinin receptors. Our observation that the BK-1r antagonist also prolonged the time for complete flow cessation after light/dye injury indicates that BK-1r-dependent signaling plays a crucial role in the stabilization phase of thrombus formation.
An interesting and potentially important observation in this study is that an ET-1A receptor antagonist was as effective as the BK-1r antagonist in preventing the Ang II-mediated acceleration of flow cessation during thrombus formation. The similarity of the protective responses afforded by antagonists to BK-1r and ET-1Ar suggests that the 2 receptors act through a common mechanism. Ang II and its metabolites are known to stimulate the release of PAI-1, 34, 35 which would impair fibrinolysis and enhance thrombus development. 34 -36 In this regard, it is noteworthy that both bradykinin and endothelin can mediate an increased expression of PAI-1. 32, 37 Heterodimerization of Ang II and bradykinin receptors represents another potential mechanism; however, such interactions have been demonstrated for AT 1 r and BK-2r, 38 neither of which appears to play a role in our in vivo model. Although it is well established that Ang II can elicit endothelin release from endothelial cells by engaging AT 1 r, 39 it remains unclear if/how ET-1 production and release by endothelial cells are linked to AT 2 r and/or BK-1r. Additional support for a role for ET-1 in thrombus formation is provided by reports describing the ability of ET-1 to impair fibrinolysis via increased PAI expression, 37 to elicit a dose-dependent increase in plasma thrombinantithrombin levels, to increase the expression of von Willebrand factor on endothelial cells, and to elicit thrombus formation in the rat mesenteric microvasculature. 15, 16 There is strong evidence linking the AT 4 r to fibrinolysis and thrombosis. AT 4 r activation appears to result in increased active PAI-1 levels in murine plasma and an impairment of fibrinolysis. 25 This contention is supported by experiments demonstrating that AT 4 r-deficient (IRAP Ϫ/Ϫ ) mice exhibit a prolongation of arterial thrombus formation, 25 whereas PAI-1 antagonism prevents thrombosis. 40 AT 4 r-mediated impairment of fibrinolysis is consistent with our observation that Divalinal prolonged the time to flow cessation but not the initiation phase of thrombus development in Ang II-infused mice. The possibility that impaired fibrinolysis accounts for the shared actions of AT 4 r, ET-1Ar, and BK-1r on the flow cessation response in mice receiving Ang II is supported by reports linking both endothelin and bradykinin to impaired fibrinolysis via PAI-1 induction, 32, 37 as well as evidence that links AT 4 r signaling to endogenous endothelin. 41 Furthermore, we demonstrate in this study that chronic Ang II infusion results in a significantly elevated PAI-1 level in mouse plasma. Although connections between the different receptors evaluated in this study are suggested by circumstantial evidence in the literature, it is clear that additional work is needed to more clearly define how these receptor populations interact to mediate Ang II-induced microvascular thrombosis.
Perspectives
Although clinical and experimental evidence clearly implicate Ang II in the genesis of atherothrombosis, our findings indicate that the prothrombotic effects of the peptide also extend to the microcirculation. However, unlike Ang IImediated large vessel thrombosis, which involves activation of AT 1 r, the response elicited in arterioles does not appear to involve classical AT 1 r stimulation. Instead, Ang II-mediated microvascular thrombosis involves the activation of AT 2 r and AT 4 r, with the former mediating thrombus initiation and the latter thrombus stabilization. AT 1 r and AT 4 r appear to interact with BK-1 and ET-1A receptors to mediate microvascular thrombus development. These findings suggest several novel therapeutic avenues for the prevention of microvascular thrombosis and small vessel disease that may result from chronic hypertension and other CVD risk factors.
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Supplementary Figures and Legends.
Figure S1: Thrombus development in cremaster muscle arterioles (panels A&C) and venules (panels B&D) of mice implanted (for 14 days) with either a saline-(panels A&B) or AngII-loaded (panels C&D) pump. WT=wild type mice, Saline=saline-loaded pump for 2 wks, AngII = angiotensin II loaded pump for 2 wks, ***indicates p<0.001 compared to corresponding control group. 
Figure 3S:
Aggregation velocity of murine platelets exposed to thrombin. Panel A shows the normalized velocity of platelet aggregation (Vn) as a function of thrombin concentration, from which an EC 50 value of 0.63 U/ml was derived. Panel B compares the platelet aggregation response of WT platelets exposed to either 1 nmol/l AngII alone (n=3), 0.63 U/ml thrombin alone (n=6), or to 0.63 U/ml thrombin with prior exposure to 1 nmol/l AngII (n=5). * denotes p<0.01 compared to AngII alone, # denotes p<0.01 compared to thrombin alone.
Vn, relative units U/ml nM
